TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8334946

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2 initially, increased by 250 mg/m2 to a maximum of 1,000 mg/m2, administered in cycles every 4 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (group A treated for 3 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (group B treated for over 12 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (overall treatment)
Number of subjects: 21
Study: 3819345

Group type: EXPERIMENTAL
Intervention: Geriatrics clinic with an interdisciplinary team
Number of subjects: 26

Group type: COMPARATOR
Intervention: General medical clinic without an interdisciplinary team
Number of subjects: 26
Study: 768512

Group type: EXPERIMENTAL
Intervention: Antibacterial impregnated dressings (nitrofurazone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-antibacterial impregnated dressings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrofurazone dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both dressing types
Number of subjects: 0
Study: 31818839

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention including daily weighing, tracking weight using an app, planning daily actions for weight loss, and weekly reflection on action plans.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Daily self-weighing without further support (control group).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Daily self-weighing (control group).
Number of subjects: 100
Study: 27732431

Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) at lower inflation pressure
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) at higher inflation pressure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC)
Number of subjects: 32
Study: 25881274

Group type: EXPERIMENTAL
Intervention: Trialist app intervention group
Number of subjects: 244

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 244
Study: 23892493

Group type: EXPERIMENTAL
Intervention: DAILIES TOTAL1 (DT1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: C1D (Clariti 1day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: AVTE (1-DAY ACUVUE TRUEYE)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cumulative Comfort (CC) for DT1
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cumulative Comfort (CC) for asymptomatic group
Number of subjects: 104
Study: 21278424

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: C reactive protein (CRP)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Total white blood cells count (WBC)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 328
Study: 19471293

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 57
Study: 17902334

Group type: COMPARATOR
Intervention: Full-time Essix retainer wear
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Part-time Essix retainer wear
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (Full-time and Part-time)
Number of subjects: 60
Study: 15243483

Group type: EXPERIMENTAL
Intervention: Wand Plus injection system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study: 11692587

Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg orally daily starting on postoperative day 1 for 14 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no Sotalol)
Number of subjects: 80
Study: 9130032

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (METH, 125 mg i.v. infusion followed by 40 mg/d orally for 4 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (METH, 40 mg/d orally for 4 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 20
Study: 7967919

Group type: EXPERIMENTAL
Intervention: Exclusion diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrefined carbohydrate, fiber-rich diet
Number of subjects: 0
Study: 3310197

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg) administered by intravenous injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered by intravenous injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of omeprazole and placebo
Number of subjects: 0
Study: 31690970

Group type: EXPERIMENTAL
Intervention: Closed-set logatome test
Number of subjects: 25
Study: 29522236

Group type: EXPERIMENTAL
Intervention: Routine intake forms with SOGI questions
Number of subjects: 491

Group type: COMPARATOR
Intervention: Routine intake forms (control)
Number of subjects: 491
Study: 27606710

Group type: EXPERIMENTAL
Intervention: Specialized training for therapists (including theoretical, technical, and supervised practical training)
Number of subjects: 79
Study: 25663281

Group type: EXPERIMENTAL
Intervention: Resistance training program (8 weeks, 3 days/week, 70% of 6 RM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study: 23083533

Group type: EXPERIMENTAL
Intervention: Subjective fatigue (increased fatigue class)
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Subjective fatigue (persistent fatigue class)
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Subjective fatigue (decreased fatigue class)
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Subjective fatigue (persistent energy class)
Number of subjects: 2781

Group type: COMPARATOR
Intervention: Cognitive function and everyday functioning
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Decline rates of subjective fatigue
Number of subjects: 2781
Study: 20810853

Group type: EXPERIMENTAL
Intervention: Single‐fraction radiation therapy of 700 cGy immediately postoperatively (within seventy‐two hours)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single‐fraction radiation therapy
Number of subjects: 45
Study: 19023429

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate vaginal gel
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1644
Study: 16442388

Group type: EXPERIMENTAL
Intervention: Direct stenting without balloon predilatation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Predilatation
Number of subjects: 1000
Study: 15261637

Group type: EXPERIMENTAL
Intervention: Standard honesty appeal with varying questionnaire types
Number of subjects: 4140

Group type: EXPERIMENTAL
Intervention: Strong honesty appeal with varying questionnaire types
Number of subjects: 4140

Group type: EXPERIMENTAL
Intervention: Interaction of honesty appeal and questionnaire type
Number of subjects: 4140

Group type: EXPERIMENTAL
Intervention: Identical question wording across questionnaire types
Number of subjects: 4140
Study: 11777234

Group type: EXPERIMENTAL
Intervention: Wedge matrix resection (WMR)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Nail matrix phenolization (NMP)
Number of subjects: 110
Study: 9265937

Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 514
Study: 8257492

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg rhRlx intravenous (iv)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.75 mg rhRlx intracervical
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1.5 mg rhRlx intravaginal
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0 mg rhRlx (placebo) intravaginal
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1 mg rhRlx intravaginal
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6 mg rhRlx intravaginal
Number of subjects: 51
Study: 2876745

Group type: EXPERIMENTAL
Intervention: Bendrofluazide or Propranolol
Number of subjects: 2765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2765

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2765

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 2765

Group type: EXPERIMENTAL
Intervention: Biochemical variables
Number of subjects: 2765
Study: 29313746

Group type: EXPERIMENTAL
Intervention: Calorie-Restricted (CR) diet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resveratrol (600 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27544720

Group type: EXPERIMENTAL
Intervention: Post-menarcheal growth assessment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Height at the moment of menarche
Number of subjects: 106
Study: 24122760

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Control group (chemotherapy without bevacizumab)
Number of subjects: 1076
Study: 22514150

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 80 mg/day × 2 days before and 40 mg/day × 30 days after PCI
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin treatment
Number of subjects: 1100
Study: 20732527

Group type: EXPERIMENTAL
Intervention: Modified adhesive closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional wire closure
Number of subjects: 0
Study: 18403272

Group type: EXPERIMENTAL
Intervention: High-dose cannabis (7%)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose cannabis (3.5%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 38
Study: 16679760

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14620385

Group type: EXPERIMENTAL
Intervention: Wood creosote (45, 90, 135, 180, and 225 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wood creosote (up to 225 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wood creosote
Number of subjects: 40
Study: 10785303

Group type: EXPERIMENTAL
Intervention: Photac‐Fil Quick with various conditioners
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji II LC with various conditioners
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji IX GP with various conditioners
Number of subjects: 30

Group type: COMPARATOR
Intervention: No conditioner applied to Photac‐Fil Quick
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conditioned specimens of Fuji II LC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-conditioned specimens of Fuji IX GP
Number of subjects: 30
Study: 8890679

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluoxetine (all doses combined)
Number of subjects: 200
Study: 1315662

Group type: EXPERIMENTAL
Intervention: Inactive status
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Missed visits
Number of subjects: 175
Study: 6367325

Group type: EXPERIMENTAL
Intervention: Subcutaneous dihydroergotamine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 30825982

Group type: EXPERIMENTAL
Intervention: Canine (KNM‐LS 18354) attributed to Kamoyapithecus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canine tip (KNM‐LS 18352) attributed to Kamoyapithecus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KNM‐LS 1, a smaller lower canine
Number of subjects: 0
Study: 30201053

Group type: EXPERIMENTAL
Intervention: NET combined with case management
Number of subjects: 340

Group type: COMPARATOR
Intervention: Improved treatment as usual (iTAU)
Number of subjects: 340
Study: 26729277

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (GBP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Matched hypocaloric diet (DT)
Number of subjects: 28
Study: 23212185

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patches (TFPs) 25 μg, two patches placed 12 h before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches of identical size
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (TFPs and placebo)
Number of subjects: 40
Study: 22851577

Group type: EXPERIMENTAL
Intervention: Saline infusion after exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intralipid infusion after exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intralipid infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prior exercise
Number of subjects: 8
Study: 21067614

Group type: EXPERIMENTAL
Intervention: Theory-based intervention (educational symposium)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Printed copy of the clinical practice guideline (control)
Number of subjects: 210
Study: 17112703

Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 50
Study: 16314592

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for LPSS patients
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: LPSS patients
Number of subjects: 1503

Group type: COMPARATOR
Intervention: MI comparison group
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Change in ESSI score
Number of subjects: 1503
Study: 11879715

Group type: EXPERIMENTAL
Intervention: Simvastatin 20-mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10434815

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study: 7575120

Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion with high flow rate (869 +/- 122 mL/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isolated limb perfusion with low flow rate (286 +/- 62 mL/min)
Number of subjects: 15
Study: 2322172

Group type: EXPERIMENTAL
Intervention: Composite resins (four types)
Number of subjects: 102
Study: 6993095

Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 0
Study: 30826796

Group type: EXPERIMENTAL
Intervention: Spontaneous adverse event (AE) collection
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Details of specific prompts used to ascertain AE data
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Reporting of trial withdrawals
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Withdrawals due to AEs
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Analysis of patients with at least one event
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Formal hypothesis testing for binary outcomes
Number of subjects: 184
Study: 27777163

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 86

Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 86
Study: 26575524

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice per day (BID)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study: 25051209

Group type: EXPERIMENTAL
Intervention: Weight-Bearing (WB) exercise
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Non-Weight-Bearing (NWB) exercise
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 22487032

Group type: EXPERIMENTAL
Intervention: Hippocampal learning process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Striatal learning process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of two delta rule learning processes
Number of subjects: 0
Study: 19279300

Group type: EXPERIMENTAL
Intervention: High-fiber diet (50 g total and 25 g soluble fiber)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-fiber diet (24 g total and 8 g soluble fiber)
Number of subjects: 13
Study: 17250692

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE) therapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 16241917

Group type: EXPERIMENTAL
Intervention: Group visits and computer-assisted consultations
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional out-patient consultations
Number of subjects: 116
Study: 12151282

Group type: EXPERIMENTAL
Intervention: Depression (measured by SelfCARE-D scale)
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Depression in males and individuals aged under 70 years
Number of subjects: 2584
Study: 9523656

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 303
Study: 7521090

Group type: EXPERIMENTAL
Intervention: 4 mg DOX once in the AM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4 mg DOX once in the PM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 8 mg DOX once in the AM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 8 mg DOX once in the PM
Number of subjects: 48
Study: 2683019

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g taken 1/2 h before breakfast and at bedtime)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29664896

Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg daily for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prazosin (in optimal treatment exposure subgroup)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prazosin (in individuals with high diastolic blood pressure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prazosin (in individuals with low diastolic blood pressure)
Number of subjects: 36
Study: 27187437

Group type: EXPERIMENTAL
Intervention: Work-related self-affirming implementation intention (WS-AII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control implementation intention (C-II)
Number of subjects: 0
Study: 26441179

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 486

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 486
Study: 23117245

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1371
Study: 21051493

Group type: EXPERIMENTAL
Intervention: Remifentanil concentrations (CeREMI) at 2, 4, or 6 ng m⁻¹ with propofol fixed at 3 µg ml⁻¹
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPI, HR, and MAP
Number of subjects: 0
Study: 18314473

Group type: EXPERIMENTAL
Intervention: Intervention materials of varying personalization (groups 1 and 2)
Number of subjects: 23340

Group type: COMPARATOR
Intervention: Control group (group 5)
Number of subjects: 23340
Study: 16562414

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Written Feedback (WF)
Number of subjects: 222
Study: 14601228

Group type: EXPERIMENTAL
Intervention: Contreet Foam dressing
Number of subjects: 25
Study: 12144212

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 23

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 23
Study: 9627304

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) therapy
Number of subjects: 0
Study: 8157550

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg po
Number of subjects: 6
Study: 3277082

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diazepam and Phenytoin (DZ/DPH)
Number of subjects: 36
Study: 31051498

Group type: EXPERIMENTAL
Intervention: AA-60 (8 AAs, 60 mmol/L Na+)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AA-30 (5 AAs, 30 mmol/L Na+)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AA-60
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study: 28691601

Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Motor-assisted cycle training
Number of subjects: 27
Study: 26148930

Group type: EXPERIMENTAL
Intervention: MPC injections (150 million cells)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MPC injections (25 million cells)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MPC injections (75 million cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (mock procedures)
Number of subjects: 60
Study: 23930808

Group type: EXPERIMENTAL
Intervention: Scaled Path Length Entropy (SPLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hurst exponent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sample entropy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiscale entropy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Path Length Entropy (PLE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate data evaluation
Number of subjects: 0
Study: 21562233

Group type: EXPERIMENTAL
Intervention: Breakfast (B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No breakfast (NB)
Number of subjects: 12
Study: 19108786

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 319

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 319
Study: 16816065

Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 68
Study: 14641260

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 140
Study: 11187566

Group type: EXPERIMENTAL
Intervention: Telecare
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 46